EA: Top Gyn Cancer Abstracts

CME

Conference to Clinic: Expert Analysis of the Top Gynecologic Cancer Studies From the 2023 Oncology Meeting in Chicago

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 03, 2023

Expiration: August 02, 2024

Lauren Prescott
Lauren Prescott, MD, MPH
Ritu Salani
Ritu Salani, MD, MBA

Activity

Progress
1
Course Completed

Introduction

In this activity, Lauren Prescott, MD, MPH, and Ritu Salani, MD, MBA, share their thoughts on key new data that were presented at the 2023 American Society of Clinical Oncology (ASCO) annual meeting for endometrial, cervical, and ovarian cancers, with a focus on new data likely to change the standards of care for these gynecologic cancers. 

Please note that the slide thumbnails in this activity link to the PowerPoint slidesets associated with this program which also can be found here. The slideset can be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: Once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a healthcare professional providing patient care, how many patients with gynecologic cancer do you see in a typical month?

In your consultations with patients with advanced or recurrent endometrial cancer, which of the following patient populations would you tell them saw progression-free survival (PFS) benefit with the addition of dostarlimab to standard of care first-line chemotherapy?

Based on data reported from the phase III KEYNOTE-826 trial that enrolled adults with persistent, recurrent, or metastatic cervical cancer and no previous systemic chemotherapy, the addition of pembrolizumab to chemotherapy with or without bevacizumab would be recommended for patients with what tumor PD-L1 combined positive score (CPS) expression level?

Your patient with high-risk, HER2-positive, BRCA mutation–negative, high-grade serous ovarian cancer has evidence of progression (by PET/CT imaging) within 6 months of starting therapy with carboplatin and paclitaxel.

Which of the following FDA-approved treatment options has demonstrated improved survival in this patient population?

Which of the following significant findings was reported from the phase III DUO-O trial evaluating the addition of durvalumab (durva) to platinum-based chemotherapy plus bevacizumab (bev) treatment and to bev with or without olaparib (olap) maintenance in patients with newly diagnosed, advanced stage III-IV, ovarian cancer without a tumor BRCA mutation?